An increase in the open sale of cannabis products in Europe has raised questions around the possible legal and commercial status of these products. The products are marketed for their low THC (tetrahydrocannabinol) content, which sellers claim exempt them from control by drug laws, or as sources of CBD (cannabidiol). This publication presents an initial overview of the situation, covering the types of low-THC product available, user profiles, associated harms and regulatory responses in Europe. Low-THC products that take forms similar to illicit cannabis products, such as smoking mixtures, oils and edibles, are a primary focus of this study. The report highlights the challenges facing policymakers and suppliers of low-THC products, including the legal status of the products and the regulatory frameworks that may apply to their sale.
- Roadmap for key populations advocates navigating the global fund
- The Harms of Incarceration: The evidence base and human rights framework for decarceration and harm reduction in prisons
- Period poverty in prisons during the COVID-19 pandemic: Submission to the UN Special Rapporteur on health
- Synthetic Drugs in East and Southeast Asia: latest developments and challenges 2021
- Turning off the tap: The state of HIV prevention funding in Southern Africa
- European Drug Report 2021
- Quality standards of civil society involvement in drug policies
- Survey of client satisfaction with opioid substitution program in western Georgia
- 1st Brandenburg Forum (BBF) in Geneva "Building bridges between the drug policy and human rights regimes of the United Nations"